Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction.
about
Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?"Advances in the management of heart failure: the role of ivabradineBlood Pressure Management in Hemodialysis Patients: What We Know And What Questions Remain.Evaluating beneficial drug effects in a non-interventional setting: a review of effectiveness studies based on Swedish Prescribed Drug Register data.Emerging role of liver X receptors in cardiac pathophysiology and heart failure.Prevalence and prognostic impact of kidney disease on heart failure patients.Analysis Treatment Guideline versus Clinical Practice Protocol in Patients Hospitalized due to Heart FailureAchievement of a target dose of bisoprolol may not be a preferred option for attenuating pressure overload-induced cardiac hypertrophy and fibrosisRed cell distribution width and mortality in acute heart failure patients with preserved and reduced ejection fraction.Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial.Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions.General practitioners' adherence to chronic heart failure guidelines regarding medication: the GP-HF study.Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis.A Practical Comprehensive Approach to Management of Acute Decompensated Heart Failure.Risk of Cardiovascular Events in Patients With Diabetes Mellitus on β-Blockers.Clinical utility of sympathetic blockade in cardiovascular disease management.Prevalence and associated factors for decreased appetite among patients with stable heart failure.Association between enrolment in a heart failure quality registry and subsequent mortality-a nationwide cohort study.Heart failure in Tanzania and Sweden: Comparative characterization and prognosis in the Tanzania Heart Failure (TaHeF) study and the Swedish Heart Failure Registry (SwedeHF).Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model.Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial.Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study.Chronic heart failure management in primary healthcare in Poland: Results of a nationwide cross-sectional study.Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology.A comprehensive population-based characterization of heart failure with mid-range ejection fraction.Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients.Heart rate response and functional capacity in patients with chronic heart failure with preserved ejection fraction.[New therapy concepts for heart failure with preserved ejection fraction].Screening for heart transplantation and left ventricular assist system: results from the ScrEEning for advanced Heart Failure treatment (SEE-HF) study.Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction.Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction.Global Public Health Burden of Heart FailureAssociation is not causation: treatment effects cannot be estimated from observational data in heart failureHeart Failure with Mid-range Ejection Fraction: Lessons from CHARM
P2860
Q26785931-E0A4BD18-2F5E-4B98-A12F-6FF4F067B289Q28072418-589E66C7-8E82-4E12-B5A3-90460E130018Q30235413-AADB416B-3070-449C-9A4A-2D8BBCEEA1D8Q31147482-50486AB6-472F-4F8C-834B-CB30C72D5FA4Q36322805-8FC395A8-79F9-4F20-8E34-4CBFC28A5041Q36517260-64220200-96E5-447C-8FBF-7C2BBF92340CQ36738240-CF20CD93-8377-4AF8-A783-423A57A77B3DQ37288326-5668DB7D-5237-4584-A75C-727C6CB62D66Q37357329-93B9E784-C6F5-4455-8B7D-357EC96D6DE6Q37390767-097A88DA-2F51-4068-B6B9-46F7C5191769Q37710165-A5F2CB44-4D02-4D3B-9017-E6D721E07E46Q38629193-464C5077-FFCE-479D-8882-46E3C10AB88FQ38638655-416C74F5-898E-4794-8CEC-02D2EFE84CCDQ38754697-9929E581-7E8C-4576-ADB5-323D34E64958Q38755607-9301B8A0-9DF6-4119-865B-34E7CA68D28BQ39177907-AD24126D-F807-4545-AAA1-54718B53F45DQ39995130-5E290B07-F9E9-439B-A569-8F4D81BC84E8Q40322592-25693D9B-B6C1-4DF1-B3C7-E39FDCF7ECC5Q40660490-7DBF2715-43C8-432A-9B9C-A8A4EB9763B5Q41203153-6ED97373-8684-4C7B-960D-4B6ED8CB8877Q41250771-03DFD1F3-3A6F-44A8-84F0-1C75FC39DCEFQ41675024-D2C6B6FF-4674-414B-88F9-712B48FFD421Q47429906-F4D9FD39-1676-471D-B587-30F5A2CC7E08Q47890686-E1C56F2B-85EE-473C-980E-7890D660F88AQ49833968-CDCB8646-57DA-4BDC-B58E-DA2850B8C252Q52323086-333F645B-92A7-416D-9C4E-AF4B073306D0Q52382040-2ED1791C-2597-41CF-B814-47D8DA4068E0Q52869074-E678D10C-6309-4CFD-85FD-BC346295AF8CQ53053988-76968ECE-EB23-407C-9778-D0EFF142EFFAQ55182135-69E1C688-AA85-4064-8DFF-948CB13C2551Q55332339-AC914062-400A-4519-9821-DB9C51F56924Q55498546-5F261253-B618-462A-A3DB-BAFC60854B3DQ57095663-5D6C3462-2C4B-4F51-BAB3-0752D6FD0AE3Q58804164-59F53F93-C690-40FB-9E49-0037E90CBD55Q58804692-849096B5-7249-4882-8400-659308DE1C87
P2860
Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Association between use of β-b ...... d preserved ejection fraction.
@en
Association between use of β-b ...... d preserved ejection fraction.
@nl
type
label
Association between use of β-b ...... d preserved ejection fraction.
@en
Association between use of β-b ...... d preserved ejection fraction.
@nl
prefLabel
Association between use of β-b ...... d preserved ejection fraction.
@en
Association between use of β-b ...... d preserved ejection fraction.
@nl
P2093
P356
P1476
Association between use of β-b ...... d preserved ejection fraction.
@en
P2093
Lars H Lund
Magnus Edner
Ulf Dahlström
P304
P356
10.1001/JAMA.2014.15241
P407
P577
2014-11-01T00:00:00Z